Therapeutic genetic variation revealed in diverse Hsp104 homologs

  1. Zachary M March
  2. Katelyn Sweeney
  3. Hanna Kim
  4. Xiaohui Yan
  5. Laura M Castellano
  6. Meredith E Jackrel
  7. JiaBei Lin
  8. Edward Chuang
  9. Edward Gomes
  10. Corey W Willicott
  11. Karolina Michalska
  12. Robert P Jedrzejczak
  13. Andrzej Joachimiak
  14. Kim A Caldwell
  15. Guy A Caldwell
  16. Ophir Shalem
  17. James Shorter  Is a corresponding author
  1. University of Pennsylvania, United States
  2. The University of Alabama, United States
  3. Washington University in St Louis, United States
  4. Argonne National Laboratory, United States

Abstract

The AAA+ protein disaggregase, Hsp104, increases fitness under stress by reversing stress-induced protein aggregation. Natural Hsp104 variants might exist with enhanced, selective activity against neurodegenerative disease substrates. However, natural Hsp104 variation remains largely unexplored. Here, we screened a cross-kingdom collection of Hsp104 homologs in yeast proteotoxicity models. Prokaryotic ClpG reduced TDP-43, FUS, and a-synuclein toxicity, whereas prokaryotic ClpB and hyperactive variants were ineffective. We uncovered therapeutic genetic variation among eukaryotic Hsp104 homologs that specifically antagonized TDP-43 condensation and toxicity in yeast and TDP-43 aggregation in human cells. We also uncovered distinct eukaryotic Hsp104 homologs that selectively antagonized a-synuclein condensation and toxicity in yeast and dopaminergic neurodegeneration in C. elegans. Surprisingly, this therapeutic variation did not manifest as enhanced disaggregase activity, but rather as increased passive inhibition of aggregation of specific substrates. By exploring natural tuning of this passive Hsp104 activity, we elucidated enhanced, substrate-specific agents that counter proteotoxicity underlying neurodegeneration.

Data availability

All data generated or analysed during this study are included in the manuscript.

Article and author information

Author details

  1. Zachary M March

    Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2441-899X
  2. Katelyn Sweeney

    Genetics, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  3. Hanna Kim

    Biological Sciences, The University of Alabama, Tuscaloosa, United States
    Competing interests
    No competing interests declared.
  4. Xiaohui Yan

    Biological Sciences, The University of Alabama, Tuscaloosa, United States
    Competing interests
    No competing interests declared.
  5. Laura M Castellano

    Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  6. Meredith E Jackrel

    Department of Chemistry, Washington University in St Louis, St Louis, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4406-9504
  7. JiaBei Lin

    Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  8. Edward Chuang

    Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  9. Edward Gomes

    Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  10. Corey W Willicott

    Biological Sciences, The University of Alabama, Tuscaloosa, United States
    Competing interests
    No competing interests declared.
  11. Karolina Michalska

    Midwest Center for Structural Genomics, Biosciences Division, Argonne National Laboratory, Lemont, United States
    Competing interests
    No competing interests declared.
  12. Robert P Jedrzejczak

    Midwest Center for Structural Genomics, Argonne National Laboratory, Argonne, United States
    Competing interests
    No competing interests declared.
  13. Andrzej Joachimiak

    Midwest Center for Structural Genomics, Argonne National Laboratory, Argonne, United States
    Competing interests
    No competing interests declared.
  14. Kim A Caldwell

    Biological Sciences, The University of Alabama, Tuscaloosa, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1580-6122
  15. Guy A Caldwell

    Biological Sciences, The University of Alabama, Tuscaloosa, United States
    Competing interests
    No competing interests declared.
  16. Ophir Shalem

    Genetics, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  17. James Shorter

    Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, United States
    For correspondence
    jshorter@pennmedicine.upenn.edu
    Competing interests
    James Shorter, J.S. is a consultant for Dewpoint Therapeutics..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5269-8533

Funding

National Institute of General Medical Sciences (R01GM099836)

  • James Shorter

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Franz-Ulrich Hartl, Max Planck Institute for Biochemistry, Germany

Version history

  1. Received: April 1, 2020
  2. Accepted: December 14, 2020
  3. Accepted Manuscript published: December 15, 2020 (version 1)
  4. Version of Record published: January 5, 2021 (version 2)

Copyright

© 2020, March et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,695
    Page views
  • 246
    Downloads
  • 15
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Zachary M March
  2. Katelyn Sweeney
  3. Hanna Kim
  4. Xiaohui Yan
  5. Laura M Castellano
  6. Meredith E Jackrel
  7. JiaBei Lin
  8. Edward Chuang
  9. Edward Gomes
  10. Corey W Willicott
  11. Karolina Michalska
  12. Robert P Jedrzejczak
  13. Andrzej Joachimiak
  14. Kim A Caldwell
  15. Guy A Caldwell
  16. Ophir Shalem
  17. James Shorter
(2020)
Therapeutic genetic variation revealed in diverse Hsp104 homologs
eLife 9:e57457.
https://doi.org/10.7554/eLife.57457

Further reading

    1. Biochemistry and Chemical Biology
    2. Cell Biology
    Riham Ayoubi, Joel Ryan ... Carl Laflamme
    Research Advance

    Antibodies are critical reagents to detect and characterize proteins. It is commonly understood that many commercial antibodies do not recognize their intended targets, but information on the scope of the problem remains largely anecdotal, and as such, feasibility of the goal of at least one potent and specific antibody targeting each protein in a proteome cannot be assessed. Focusing on antibodies for human proteins, we have scaled a standardized characterization approach using parental and knockout cell lines (Laflamme et al., 2019) to assess the performance of 614 commercial antibodies for 65 neuroscience-related proteins. Side-by-side comparisons of all antibodies against each target, obtained from multiple commercial partners, have demonstrated that: (i) more than 50% of all antibodies failed in one or more applications, (ii) yet, ~50–75% of the protein set was covered by at least one high-performing antibody, depending on application, suggesting that coverage of human proteins by commercial antibodies is significant; and (iii) recombinant antibodies performed better than monoclonal or polyclonal antibodies. The hundreds of underperforming antibodies identified in this study were found to have been used in a large number of published articles, which should raise alarm. Encouragingly, more than half of the underperforming commercial antibodies were reassessed by the manufacturers, and many had alterations to their recommended usage or were removed from the market. This first study helps demonstrate the scale of the antibody specificity problem but also suggests an efficient strategy toward achieving coverage of the human proteome; mine the existing commercial antibody repertoire, and use the data to focus new renewable antibody generation efforts.

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Rui-Qiu Yang, Yong-Hong Chen ... Cheng-Gang Zou
    Research Article

    An imbalance of the gut microbiota, termed dysbiosis, has a substantial impact on host physiology. However, the mechanism by which host deals with gut dysbiosis to maintain fitness remains largely unknown. In Caenorhabditis elegans, Escherichia coli, which is its bacterial diet, proliferates in its intestinal lumen during aging. Here, we demonstrate that progressive intestinal proliferation of E. coli activates the transcription factor DAF-16, which is required for maintenance of longevity and organismal fitness in worms with age. DAF-16 up-regulates two lysozymes lys-7 and lys-8, thus limiting the bacterial accumulation in the gut of worms during aging. During dysbiosis, the levels of indole produced by E. coli are increased in worms. Indole is involved in the activation of DAF-16 by TRPA-1 in neurons of worms. Our finding demonstrates that indole functions as a microbial signal of gut dysbiosis to promote fitness of the host.